Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Trans-peritoneal fine needle aspiration biopsy of hilar cholangiocarcinoma is associated with disease dissemination.

Heimbach JK, Sanchez W, Rosen CB, Gores GJ.

HPB (Oxford). 2011 May;13(5):356-60. doi: 10.1111/j.1477-2574.2011.00298.x. Epub 2011 Mar 29.

2.

Staging, prognostic factors and adjuvant therapy of intrahepatic cholangiocarcinoma after curative resection.

Li T, Qin LX, Zhou J, Sun HC, Qiu SJ, Ye QH, Wang L, Tang ZY, Fan J.

Liver Int. 2014 Jul;34(6):953-60. doi: 10.1111/liv.12364. Epub 2013 Nov 20.

PMID:
24134199
3.

The impact of portal vein resection on outcomes for hilar cholangiocarcinoma: a multi-institutional analysis of 305 cases.

de Jong MC, Marques H, Clary BM, Bauer TW, Marsh JW, Ribero D, Majno P, Hatzaras I, Walters DM, Barbas AS, Mega R, Schulick RD, Choti MA, Geller DA, Barroso E, Mentha G, Capussotti L, Pawlik TM.

Cancer. 2012 Oct 1;118(19):4737-47. doi: 10.1002/cncr.27492. Epub 2012 Mar 13.

4.

The prognostic importance of lymphovascular invasion in cholangiocarcinoma above the cystic duct: a new selection criterion for adjuvant therapy?

Patel SH, Kooby DA, Staley CA 3rd, Sarmiento JM, Maithel SK.

HPB (Oxford). 2011 Sep;13(9):605-11. doi: 10.1111/j.1477-2574.2011.00335.x. Epub 2011 Jul 26.

5.

Catheter tract recurrence after percutaneous biliary drainage for hilar cholangiocarcinoma.

Kang MJ, Choi YS, Jang JY, Han IW, Kim SW.

World J Surg. 2013 Feb;37(2):437-42. doi: 10.1007/s00268-012-1844-1.

PMID:
23188530
6.

Impact of preoperative endoscopic ultrasound-guided fine needle aspiration on postoperative recurrence and survival in cholangiocarcinoma patients.

El Chafic AH, Dewitt J, Leblanc JK, El Hajj II, Cote G, House MG, Sherman S, McHenry L, Pitt HA, Johnson C, Mohamadnejad M, Al-Haddad M.

Endoscopy. 2013 Nov;45(11):883-9. doi: 10.1055/s-0033-1344760. Epub 2013 Oct 28.

PMID:
24165813
7.

Hilar cholangiocarcinoma and liver transplantation.

Heimbach J.

Transplantation. 2009 Aug 15;88(3):299-300. doi: 10.1097/TP.0b013e3181adca5a. No abstract available.

PMID:
19667928
8.

Neoadjuvant chemoradiotherapy followed by liver transplantation for unresectable cholangiocarcinoma: a single-centre national experience.

Duignan S, Maguire D, Ravichand CS, Geoghegan J, Hoti E, Fennelly D, Armstrong J, Rock K, Mohan H, Traynor O.

HPB (Oxford). 2014 Jan;16(1):91-8. doi: 10.1111/hpb.12082. Epub 2013 Apr 18.

9.

Liver transplantation for hilar cholangiocarcinoma.

Thelen A, Neuhaus P.

J Hepatobiliary Pancreat Surg. 2007;14(5):469-75. Epub 2007 Sep 28.

PMID:
17909715
10.

Impact of neoadjuvant chemoradiation on the tumor burden before liver transplantation for unresectable cholangiocarcinoma.

Panjala C, Nguyen JH, Al-Hajjaj AN, Rosser BA, Nakhleh RE, Bridges MD, Ko SJ, Buskirk SJ, Kim GP, Harnois DM.

Liver Transpl. 2012 May;18(5):594-601. doi: 10.1002/lt.22462.

11.

Liver transplantation for hilar cholangiocarcinoma.

Robles R, Sánchez-Bueno F, Ramírez P, Brusadin R, Parrilla P.

World J Gastroenterol. 2013 Dec 28;19(48):9209-15. doi: 10.3748/wjg.v19.i48.9209. Review.

12.

Gemcitabine-based adjuvant chemotherapy improves survival after aggressive surgery for hilar cholangiocarcinoma.

Murakami Y, Uemura K, Sudo T, Hayashidani Y, Hashimoto Y, Nakamura H, Nakashima A, Sueda T.

J Gastrointest Surg. 2009 Aug;13(8):1470-9. doi: 10.1007/s11605-009-0900-0. Epub 2009 May 7.

PMID:
19421824
13.

Palliative treatment with self-expandable metallic stents in patients with advanced type III or IV hilar cholangiocarcinoma: a percutaneous versus endoscopic approach.

Paik WH, Park YS, Hwang JH, Lee SH, Yoon CJ, Kang SG, Lee JK, Ryu JK, Kim YT, Yoon YB.

Gastrointest Endosc. 2009 Jan;69(1):55-62. doi: 10.1016/j.gie.2008.04.005. Epub 2008 Jul 26.

PMID:
18657806
14.

Unresectable hilar cholangiocarcinoma: multimodality approach with percutaneous treatment associated with radiotherapy and chemotherapy.

Golfieri R, Giampalma E, Renzulli M, Galuppi A, Vicenzi L, Galaverni MC, Cappelli A.

In Vivo. 2006 Nov-Dec;20(6A):757-60.

15.

Intrahepatic cholangiocarcinoma: prognostic factors after surgical resection.

Guglielmi A, Ruzzenente A, Campagnaro T, Pachera S, Valdegamberi A, Nicoli P, Cappellani A, Malfermoni G, Iacono C.

World J Surg. 2009 Jun;33(6):1247-54. doi: 10.1007/s00268-009-9970-0.

PMID:
19294467
16.

Role of hilar resection in the treatment of hilar cholangiocarcinoma.

Otani K, Chijiiwa K, Kai M, Ohuchida J, Nagano M, Kondo K.

Hepatogastroenterology. 2012 May;59(115):696-700. doi: 10.5754/hge09725.

PMID:
22469711
17.

Role of preoperative optimization of the liver for resection in patients with hilar cholangiocarcinoma type III.

Grandadam S, Compagnon P, Arnaud A, Olivié D, Malledant Y, Meunier B, Launois B, Boudjema K.

Ann Surg Oncol. 2010 Dec;17(12):3155-61. doi: 10.1245/s10434-010-1168-z. Epub 2010 Jul 1.

PMID:
20593243
18.

Neoadjuvant therapy for downstaging of locally advanced hilar cholangiocarcinoma: a systematic review.

Grendar J, Grendarova P, Sinha R, Dixon E.

HPB (Oxford). 2014 Apr;16(4):297-303. doi: 10.1111/hpb.12150. Epub 2013 Aug 26. Review.

19.

Impact of specialized multi-disciplinary approach and an integrated pathway on outcomes in hilar cholangiocarcinoma.

Gomez D, Patel PB, Lacasia-Purroy C, Byrne C, Sturgess RP, Palmer D, Fenwick S, Poston GJ, Malik HZ.

Eur J Surg Oncol. 2014 Jan;40(1):77-84. doi: 10.1016/j.ejso.2013.10.009. Epub 2013 Oct 23.

PMID:
24262111
20.

Peritoneal washings are not predictive of occult peritoneal disease in patients with hilar cholangiocarcinoma.

Martin RC 2nd, Fong Y, DeMatteo RP, Brown K, Blumgart LH, Jarnagin WR.

J Am Coll Surg. 2001 Dec;193(6):620-5.

PMID:
11768678

Supplemental Content

Support Center